Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization (scientific article published in June 1997)

cites work (P2860)

Q22241913	Q22241913
Q73062366	"IIb or not IIb or maybe IIb?" Is that the question? Or is it "which IIb and to whom?"
Q33879288	"No-reflow" phenomenon following percutaneous coronary intervention: an uncommon complication
Q77371818	"Rescue" abciximab for complicated percutaneous transluminal coronary angioplasty
Q73914281	"Rescue" utilization of abciximab for the dissolution of coronary thrombus developing as a complication of coronary angioplasty
Q35088087	"Routine invasive" versus "selective invasive" approaches to non-ST-segment elevation acute coronary syndromes management in the post-stent/platelet inhibition era.
Q43733820	1,2,4-triazolo[3,4-a]pyridine as a novel, constrained template for fibrinogen receptor (GPIIb/IIIa) antagonists
Q78251271	1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial
Q44061286	2002 Update of the Guidelines of the Spanish Society of Cardiology for Unstable Angina/Without ST-Segment Elevation Myocardial Infarction
Q37953885	2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventi
Q22241922	2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines
Q30804000	A Bayesian approach to aid in formulary decision making: incorporating institution-specific cost-effectiveness data with clinical trial results
Q37316783	A bumpy and winding but right path to domestic drug-eluting coronary stents
Q33380071	A case report of alveolar haemorrhage associated with severe thrombocytopenia induced by abciximab infusion in a patient with an acute coronary syndrome
Q95721111	A comparative study of light transmission aggregometry and automated bedside platelet function assays in patients undergoing percutaneous coronary intervention and receiving abciximab, eptifibatide, or tirofiban
Q34111637	A critical appraisal of platelet glycoprotein IIb/IIIa inhibition
Q28194376	A guide to drug use during percutaneous coronary intervention
Q28193796	A multicenter study of the tolerability of tirofiban versus placebo in patients undergoing planned intracoronary stent placement
Q33380104	A multicenter, randomized, open-label, therapeutic, and exploratory trial to evaluate the tolerability and efficacy of platelet glycoprotein IIb/IIIa receptor blocker (Clotinab) in high-risk patients with percutaneous coronary intervention
Q77535802	A perspective on the regulation of the evaluation of new antithrombotic drugs
Q44397616	A propensity analysis of the impact of platelet glycoprotein IIb/IIIa inhibitor therapy on in-hospital outcomes after percutaneous coronary intervention
Q77535805	A randomized comparison of bivalirudin and heparin in patients undergoing coronary angioplasty for postinfarction angina. Hirulog Angioplasty Study Investigators
Q51690540	A randomized trial assessing the impact of three different glycoprotein IIb/IIIa antagonists on glycoprotein IIb/IIIa platelet receptor inhibition and clinical endpoints in patients with acute coronary syndromes.
Q42536163	A randomized trial comparing the impact of a nonionic (Iomeprol) versus an ionic (Ioxaglate) low osmolar contrast medium on abrupt vessel closure and ischemic complications after coronary angioplasty
Q74519097	A randomized trial of vascular hemostasis techniques to reduce femoral vascular complications after coronary intervention
Q28191519	A randomized, placebo-controlled trial of enoxaparin after high-risk coronary stenting: the ATLAST trial
Q43812095	A risk stratification scheme for selection of a glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention based on clinical and angiographic criteria
Q77959634	A risk-benefit assessment of abciximab in angioplasty
Q36945807	A systematic review of gender differences in mortality after coronary artery bypass graft surgery and percutaneous coronary interventions.
Q44244531	A unique, low dose of intravenous enoxaparin in elective percutaneous coronary intervention
Q58976304	ACC expert consensus document on coronary artery stents
Q33751623	ACC/AHA Guidelines for Coronary Artery Bypass Graft Surgery: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1991 Guidelines for Coronary Artery Bypass Graft [...]
Q59356505	ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the M
Q88684933	Abciximab (ReoPro) Dosing Strategy for the Management of Acute Intraprocedural Thromboembolic Complications during Pipeline Flow Diversion Treatment of Intracranial Aneurysms
Q74450107	Abciximab administration and clinical outcomes after percutaneous intervention for in-stent restenosis
Q77371764	Abciximab administration and outcome after intracoronary stent implantation
Q56944772	Abciximab and bleeding during coronary surgery: results from the EPILOG and EPISTENT trials ∗ ∗A complete list of the principal investigators and study coordinators of the EPILOG (Evaluation in PTCA to Improve Long-term Outcome with abciximab GP
Q33393501	Abciximab as an adjunctive therapy for patients undergoing percutaneous coronary interventions
Q43736778	Abciximab bolus with optional infusion in intervention for ST-elevation myocardial infarction
Q77604000	Abciximab combined with angioplasty in a patient with renal artery stent subacute thrombosis
Q74600278	Abciximab for the treatment of acute distal embolization associated with internal carotid artery angioplasty
Q77700125	Abciximab in primary coronary angioplasty for acute myocardial infarction improves short- and medium-term outcomes
Q78165586	Abciximab not RGD peptide inhibits von Willebrand factor-dependent platelet activation under shear
Q54057930	Abciximab reduces mortality in diabetics following percutaneous coronary intervention.
Q41737311	Abciximab therapy in percutaneous intervention: economic issues in the United States
Q33867830	Abciximab. A pharmacoeconomic review of its use in percutaneous coronary revascularisation
Q33504164	Abciximab. An updated review of its use in ischaemic heart disease
Q40119259	Abciximab: a reappraisal of its use in coronary care
Q28196075	Abciximab: an updated review of its therapeutic use in patients with ischaemic heart disease undergoing percutaneous coronary revascularisation
Q55337905	Accuracy, reproducibility and costs of different laboratory assays for the monitoring of unfractionated heparin in clinical practice: a prospective evaluation study and survey among Swiss institutions.
Q28193854	Activated clotting times in the setting of eptifibatide use during percutaneous coronary intervention
Q46626259	Activation of platelet protein kinase C by ultraviolet light B mediates platelet transfusion-related acute lung injury in a two-event animal model
Q56928574	Acute and long-term cost implications of coronary stenting
Q48028091	Acute coronary syndromes: 2. Antiplatelet agents
Q33664183	Acute coronary syndromes: interventions.
Q34531478	Acute ischemic syndromes. Adjunctive therapy
Q35189386	Acute procedural complications and in-hospital events after percutaneous coronary interventions: eptifibatide versus abciximab
Q33504423	Acute profound thrombocytopenia after abciximab therapy during coronary angioplasty.
Q33333419	Acute profound thrombocytopenia following abciximab therapy
Q55155282	Acute scrotum after myocardial infarction.
Q44444159	Adjunctive Use of Platelet Glycoprotein IIb/IIIa Inhibitors for Carotid Angioplasty and Stent Placement: Time to Say Good Bye?
Q33339625	Administration of abciximab to patients receiving tirofiban or eptifibatide: effect on platelet function
Q34748832	Administration of glycoprotein IIb-IIIa inhibitors in patients with ST-segment elevation myocardial infarction
Q28181298	Advances in adjunctive pharmacological therapy for percutaneous coronary interventions
Q33655204	Advances in the medical management of acute coronary syndromes
Q34114460	Advances in the pharmacology of acute coronary syndrome. Platelet inhibition
Q35697376	Age and outcomes of primary percutaneous intervention for ST elevation myocardial infarction in a tertiary center-are we there yet?
Q34289859	American College of Cardiology/Society for Cardiac Angiography and Interventions Clinical Expert Consensus Document on cardiac catheterization laboratory standards. A report of the American College of Cardiology Task Force on Clinical Expert Consens
Q74197388	An introduction to provisional stenting
Q41737292	An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors
Q33803432	Analysis of number needed to treat and cost of platelet glycoprotein IIb/IIIa inhibitors in percutaneous coronary interventions and acute coronary syndromes
Q43420314	AngioJet thrombectomy and stenting for reperfusion in acute MI complicated with cardiogenic shock
Q43505150	Angiographic and clinical outcomes following acute infarct angioplasty on saphenous vein grafts
Q36940793	Angiographic and clinical outcomes of bivalirudin versus heparin in patients with acute coronary syndrome undergoing percutaneous coronary intervention
Q44588087	Angiographic variables predict increased risk for adverse ischemic events after coronary stenting with glycoprotein IIb/IIIa inhibition: results from the TARGET trial
Q37221177	Anti-inflammatory effect of abciximab-coated stent in a porcine coronary restenosis model
Q37929839	Anti-platelet therapy: glycoprotein IIb-IIIa antagonists
Q30402038	Anticoagulation in the management of non-ST-segment elevation acute coronary syndrome
Q24197614	Antiplatelet agents for chronic kidney disease
Q24200752	Antiplatelet agents for chronic kidney disease
Q37948506	Antiplatelet agents for the treatment and prevention of atherothrombosis
Q38106501	Antiplatelet and anticoagulant strategies in acute coronary syndrome: where we are in 2013.
Q24793199	Antiplatelet and anticoagulant therapy in elective percutaneous coronary intervention
Q28217915	Antiplatelet drug induced isolated profound thrombocytopenia in interventional cardiology: a review based on individual case reports
Q35752619	Antiplatelet drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
Q38075455	Antiplatelet medications and evolving antithrombotic medication
Q34111901	Antiplatelet medications and their indications in preventing and treating coronary thrombosis
Q28193855	Antiplatelet therapies in combination for the treatment of patients with stable and unstable coronary artery disease
Q37838100	Antiplatelet therapy and vascular disease: an update.
Q33671940	Antiplatelet therapy for treatment of acute coronary syndromes
Q45111432	Antiplatelet therapy in atherosclerotic cardiovascular disease
Q33331052	Antiplatelet therapy in interventional cardiology: II. Glycoprotein IIb/IIIa inhibitors
Q28219001	Antiplatelet therapy in peripheral occlusive arterial disease
Q45937919	Antiplatelet therapy. Aspirin, ticlopidine/clopidogrel, and anti-integrin agents.
Q40329892	Antiplatelet therapy: current strategies and future trends
Q46576624	Antithrombotic agents in the treatment of severe sepsis
Q34306781	Antithrombotic and thrombolytic therapy in acute cardiac care
Q74344448	Antithrombotic therapy in acute coronary syndromes
Q28174946	Antithrombotic therapy in cardiac stent patients
Q28194745	Antithrombotic therapy in the acute phase of unstable angina
Q34027525	Antithrombotic therapy in the cardiac catheterization laboratory: focus on antiplatelet agents
Q33869597	Applications of anti-platelet monitoring in catheterization laboratory
Q48383360	Applications of thrombolytic therapy
Q34147046	Appropriateness of percutaneous transluminal coronary angioplasty in stable and unstable angina pectoris. A review
Q33344475	Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia
Q44161851	Argatroban for percutaneous coronary interventions: hit or miss?
Q33894495	Arteriosclerosis and the promise of GPIIb/IIIa inhibitors in stroke
Q28185093	Aspirin in patients with coronary artery disease: is it simply irresistible?
Q52928919	Association between abciximab and length of stay in intensive care for patients undergoing percutaneous coronary intervention. A 2-stage econometric model in a naturalistic setting.
Q44397625	Association of an activated clotting time < or =250 seconds with adverse event rates after percutaneous coronary intervention using tirofiban and heparin (a TACTICS-TIMI 18 substudy).
Q33338891	Association of eptifibatide and acute profound thrombocytopenia
Q50534959	Association of two silent polymorphisms of platelet glycoprotein Ia/IIa receptor with risk of myocardial infarction: a case-control study.
Q38327059	Associations between a polymorphism in the gene encoding glycoprotein IIIa and myocardial infarction or coronary artery disease
Q37683552	Balancing the benefits and risks of antiplatelet agents in patients with non-ST-segment elevated acute coronary syndromes and undergoing percutaneous coronary intervention
Q50685269	Barriers to Early Discharge after Elective Percutaneous Coronary Intervention (BED PCI): A Single-Center Study.
Q46947043	Baseline troponin level: key to understanding the importance of post-PCI troponin elevations
Q34761510	Basic stenting
Q77761534	Bedside activated partial thromboplastin time monitoring: just a matter of time?
Q73189621	Benefit of coronary reperfusion before intervention on outcomes after primary angioplasty for acute myocardial infarction
Q35770607	Biologic therapies: what and when?
Q46095258	Bivalirudin vs heparin in percutaneous coronary intervention: a pooled analysis
Q28192328	Bivalirudin: a direct thrombin inhibitor
Q34585171	Bivalirudin: a review of its potential place in the management of acute coronary syndromes
Q34194271	Bleeding complications associated with glycoprotein IIb/IIIa inhibitors in patients 80 years of age and older undergoing percutaneous coronary intervention
Q37070782	Bleeding complications in acute coronary syndromes and percutaneous coronary intervention: predictors, prognostic significance, and paradigms for reducing risk
Q37974686	Bleeding risk and safety profile related to the use of eptifibatide: a current review
Q73197633	Bleeding risk of platelet glycoprotein IIb/IIIa receptor antagonists in broad-based practice (results from the Society for Cardiac Angiography and Interventions Registry)
Q46591692	Bleeding risks of combination vs. single antiplatelet therapy: a meta-analysis of 18 randomized trials comprising 129,314 patients
Q33869581	Bridging the gap with new strategies in acute ST elevation myocardial infarction: bolus thrombolysis, glycoprotein IIb/IIIa inhibitors, combination therapy, percutaneous coronary intervention, and "facilitated" PCI.
Q34281614	Cardiac troponin T and I and creatine kinase-MB as markers of myocardial injury and predictors of outcome following percutaneous coronary intervention
Q74191023	Cardiogenic shock
Q41701645	Cardiology. Attention shifts to the white clot
Q78638408	Cardioprotective effects of an early invasive strategy for non-ST-segment elevation acute coronary syndromes: are we all becoming "interventional" cardiologists?
Q33365668	Cardiopulmonary bypass in patients with pre-existing coagulopathy
Q44032608	Carotid Angioplasty
Q48714490	Carotid angioplasty and stenting versus carotid endarterectomy: randomized trial in a community hospital
Q42050796	Changing outcomes in percutaneous coronary interventions: a study of 34,752 procedures in northern New England, 1990 to 1997. Northern New England Cardiovascular Disease Study Group
Q73383897	Chest pain centers: moving toward proactive acute coronary care
Q73310517	Chest pain--a strong predictor of adverse cardiac events following precutaneous intervention (from the Evaluation of Platelet IIb/IIIa Inhibitor for Stenting Trial [EPISENT])]
Q77958677	Chimeric 7E3 Fab (ReoPro) decreases detectable CD11b on neutrophils from patients undergoing coronary angioplasty
Q36184702	Choice of GPIIb/IIIa antagonist in percutaneous coronary intervention: how should economic criteria be factored in?
Q46725581	Clinical and angiographic follow-up of ruptured intracranial aneurysms treated with endovascular embolization
Q39299067	Clinical approach on challenge and desensitization procedures with aspirin in patients with ischemic heart disease and nonsteroidal anti-inflammatory drug hypersensitivity.
Q56944785	Clinical benefit of glycoprotein IIb/IIIa blockade with abciximab is independent of gender
Q61669026	Clinical experience with antithrombotic drugs acting on purine receptor pathways
Q51809243	Clinical impact of abciximab on long‐term outcome after complex coronary angioplasty
Q28194398	Clinical implications of CURE and PCI-CURE in patients with the acute coronary syndrome without persistent ST-elevation
Q34585078	Clinical pharmacokinetics of tirofiban, a nonpeptide glycoprotein IIb/IIIa receptor antagonist: comparison with the monoclonal antibody abciximab
Q33500262	Clinical pharmacology of eptifibatide
Q43796125	Clinical pharmacology of higher dose eptifibatide in percutaneous coronary intervention (the PRIDE study).
Q28193162	Clinical trials of glycoprotein IIb/IIIa inhibitors
Q36164019	Clinical use of enoxaparin in the management of non-ST segment elevation acute coronary syndromes
Q28177271	Clinical use of new antithrombotic therapies for medical management of acute coronary syndromes
Q34543634	Clinically useful monoclonal antibodies in treatment
Q74540844	Coadministration of low-dose urokinase and abciximab in thrombolysis for lower limb ischemia. a safety study
Q54035550	Combination of a direct thrombin inhibitor and a platelet glycoprotein IIb/IIIa blocking peptide facilitates and maintains reperfusion of platelet-rich thrombus with alteplase.
Q33735575	Combination therapy for acute myocardial infarction: glycoprotein IIb/IIIa inhibitors plus thrombolysis.
Q34500263	Combination therapy in peripheral vascular disease: the rationale of using both thrombolytic and antiplatelet drugs.
Q73356871	Combination therapy with tirofiban and enoxaparin in acute coronary syndromes
Q34069680	Combination therapy: management of acute myocardial infarction in the new millennium
Q42611184	Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study
Q56945043	Combining thrombolysis with the platelet glycoprotein IIb/IIIa inhibitor lamifiban: results of the Platelet Aggregation Receptor Antagonist Dose Investigation and Reperfusion Gain in Myocardial Infarction (PARADIGM) Trial
Q28191774	Common variations in platelet glycoproteins: pharmacogenomic implications
Q43812949	Comparison of GP IIB/IIIA inhibitors and their activity as measured by aggregometry, flow cytometry, single platelet counting, and the rapid platelet function analyzer
Q56944673	Comparison of benefits and complications of hirudin versus heparin for patients with acute coronary syndromes undergoing early percutaneous coronary intervention
Q28194785	Comparison of clopidogrel versus ticlopidine for prevention of minor myocardial injury after elective coronary stenting
Q51806173	Comparison of effect of glycoprotein IIb/IIIa inhibitors during percutaneous coronary interventions on risk of hemorrhagic stroke in patients ≥75 years of age versus those <75 years of age
Q44635344	Comparison of effectiveness and safety of three different antithrombotic regimens (bivalirudin, eptifibatide, and heparin) in preventing myocardial ischemia during percutaneous coronary intervention
Q77616445	Comparison of efficacy and complication rates after percutaneous coronary interventions in patients with and without renal insufficiency treated with abciximab
Q44136330	Comparison of one-year outcomes following coronary artery stenting in diabetic versus nondiabetic patients (from the Enhanced Suppression of the Platelet IIb/IIIa Receptor With Integrilin Therapy [ESPRIT] Trial).
Q77178277	Complications associated with combined use of abciximab and an intracoronary thrombolytic agent (urokinase or tissue-type plasminogen activator)
Q42026917	Complications of cardiac catheterization: a single-center study.
Q28212068	Contemporary management of acute coronary syndrome
Q73245554	Coronary Angioplasty
Q33802871	Coronary microembolization--its role in acute coronary syndromes and interventions
Q30658145	Coronary perforation during percutaneous coronary intervention in the era of abciximab platelet glycoprotein IIb/IIIa blockade: an algorithm for percutaneous management.
Q93913200	Coronary stenting and use of abciximab
Q45918932	Correlation of inhibition of platelet aggregation with cardiovascular and bleeding outcomes in acute coronary syndromes.
Q52069310	Cost effectiveness of abciximab during routine medical practice.
Q44027345	Cost efficacy of platelet glycoprotein IIb/IIIa antagonists in clinical trials and clinical practice
Q48027994	Cost-effectiveness analysis of abciximab: a Canadian hospital perspective
Q28165924	Costs and cost effectiveness of low molecular weight heparins and platelet glycoprotein IIb/IIIa inhibitors: in the management of acute coronary syndromes
Q74434403	Costs and effects in therapy for acute coronary syndromes: the case of abciximab in high-risk patients undergoing percutaneous transluminal coronary angioplasty in the EPIC study. Evaluation of 7E3 for the Prevention of Ischemic Complications
Q73447985	Costs and effects of combining stenting and abciximab (ReoPro) in daily practice
Q77811118	Creatine kinase leaks, myocardial necrosis, and prognosis after percutaneous coronary interventions
Q88196076	Current Antithrombotic Therapy in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Interventions
Q28200685	Current developments in anti-platelet therapy
Q43680770	Current perspectives on British use of adjunctive therapies during coronary interventions
Q34019043	Current status of cardiac surgery in the abciximab-treated patient
Q28199725	Current strategies with eptifibatide and other antiplatelet agents in percutaneous coronary intervention and acute coronary syndromes
Q40109843	Current treatment and future prospects for the management of acute coronary syndromes: consensus recommendations of the 1997 ushuaia conference, tierra del fuego, Argentina
Q37076393	Current update on glycoprotein IIb-IIIa and direct thrombin inhibition in percutaneous coronary intervention for non-ST elevation acute coronary syndromes: balancing bleeding risk and antiplatelet efficacy
Q35107087	Deaths associated with platelet glycoprotein IIb/IIIa inhibitor treatment
Q36614138	Debate of adjunctive pharmacology for percutaneous coronary intervention: thrombin inhibitors and clopidogrel are enough
Q33411512	Decline in platelet count and long-term post-PCI ischemic events: implication of the intra-aortic balloon pump
Q58071767	Design and dosimetry of a novel 90y beta source to prevent restenosis after angioplasty
Q35925710	Development of glycoprotein IIb-IIIa antagonists: translation of pharmacodynamic effects into clinical benefit
Q77707986	Diabetic patients treated with abciximab and intracoronary stenting
Q33781183	Diagnosis and management of patients with unstable angina
Q77839691	Differences among the parenteral platelet glycoprotein IIb/IIIa inhibitors and implications for treatment
Q52533099	Different response to balloon angioplasty of carotid and coronary arteries: effects on acute platelet deposition and intimal thickening.
Q28195598	Differential benefits and outcomes of tirofiban vs abciximab for acute coronary syndromes in current clinical practice
Q31151460	Differential effect of the GPIIb/IIIa antagonist orbofiban on human platelet aggregate formation in vitro
Q34684090	Direct thrombin inhibitors for percutaneous coronary intervention in the current era of platelet glycoprotein IIb/IIIa inhibition
Q24805692	Disagreements between central clinical events committee and site investigator assessments of myocardial infarction endpoints in an international clinical trial: review of the PURSUIT study
Q35976822	Dosing of unfractionated heparin in acute coronary syndromes.
Q33332127	Drug-Induced Thrombocytopenia: Is it a Serious Concern for Glycoprotein IIb/IIIa Receptor Inhibitors?
Q33339739	Drug-induced and drug-dependent immune thrombocytopenias
Q33334283	Drug-induced thrombocytopenia in the coronary care unit
Q24800495	Early and long-term outcome of elective stenting of the infarct-related artery in patients with viability in the infarct-area: Rationale and design of the Viability-guided Angioplasty after acute Myocardial Infarction-trial (The VIAMI-trial)
Q24245014	Early invasive versus conservative strategies for unstable angina & non-ST-elevation myocardial infarction in the stent era
Q24236794	Early invasive versus conservative strategies for unstable angina and non-ST elevation myocardial infarction in the stent era
Q24247344	Early invasive versus ischemia-guided strategies for unstable angina & non-ST-elevation myocardial infarction
Q74050749	Early mobilization after protamine reversal of heparin following implantation of phosphorylcholine-coated stents in totally occluded coronary arteries
Q73749792	Early use of glycoprotein IIb/IIIa inhibitors in the ED treatment of non-ST-segment elevation acute coronary syndromes: a local quality improvement initiative
Q73081825	Economic impact of GPIIB/IIIA blockade after high-risk angioplasty: results from the RESTORE trial. Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis
Q42673564	Economic value of thrombolysis with adjunctive abciximab in patients with subacute peripheral arterial occlusion
Q77375293	Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. An industry perspective on health economics studies
Q77375230	Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Consortium perspective: what constitutes a useful economic study?
Q30573719	Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Use of abciximab: comparative economic data.
Q35048369	Effect of a dual drug-coated stent with abciximab and alpha-lipoic Acid in a porcine coronary restenosis model
Q74228087	Effect of a humanized monoclonal antibody to von Willebrand factor in a canine model of coronary arterial thrombosis
Q44193416	Effect of abciximab on angiographic complications during percutaneous coronary stenting in the Evaluation of Platelet IIb/IIIa Inhibition in Stenting Trial (EPISTENT).
Q43516698	Effect of abciximab on cardiac enzyme elevation after transluminal extraction atherectomy (TEC) in high-risk saphenous vein graft lesions: comparison with a historical control group
Q54471461	Effect of abciximab on late adverse events in patients with diabetes mellitus undergoing stent implantation.
Q74353905	Effect of abciximab on the outcome of emergency coronary artery bypass grafting after failed percutaneous coronary intervention
Q92480133	Effect of antiplatelet therapy on cardiovascular and kidney outcomes in patients with chronic kidney disease: a systematic review and meta-analysis
Q43796170	Effect of eptifibatide on angiographic complications during percutaneous coronary intervention in the IMPACT--(Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis) II Trial
Q41702106	Effect of glycoprotein IIb/IIIa inhibition without thrombolytic therapy on reperfusion in acute myocardial infarction: results of ReoMI pilot study
Q28185738	Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial
Q57801368	Effect of tailored use of tirofiban in patients with Non-ST-elevation acute coronary syndrome undergoing percutaneous coronary intervention: a randomized controlled trial
Q56944402	Effect of uncoated stenting versus balloon angioplasty alone of long coronary (>20 mm) versus shorter narrowings on One-Year Event-Free survival
Q73442885	Effectiveness and safety of abciximab after failed thrombolytic therapy
Q42611328	Effectiveness of early coronary angioplasty and abciximab for failed thrombolysis (reteplase or alteplase) during acute myocardial infarction (results from the GUSTO-III trial). Global Use of Strategies To Open occluded coronary arteries
Q44123405	Effectiveness of tirofiban, eptifibatide, and abciximab in minimizing myocardial necrosis during percutaneous coronary intervention (TEAM pilot study).
Q52973694	Effects of abciximab and tirofiban on vitronectin receptors in human endothelial and smooth muscle cells.
Q77933836	Effects of platelet glycoprotein IIb/IIIa inhibition with abciximab on thrombin generation and activity during percutaneous coronary intervention
Q28196678	Effects of roxifiban on platelet aggregation and major receptor expression in patients with coronary artery disease for the Roxifiban Oral Compound Kinetics Evaluation Trial-I (ROCKET-I Platelet Substudy)
Q44506548	Effects of the glycoprotein IIb/IIIa antagonist Roxifiban on P-selectin expression, fibrinogen binding, and microaggregate formation in a phase I dose-finding study: no evidence for platelet activation during treatment with a glycoprotein IIb/IIIa a
Q43610369	Effects on thrombin generation of the platelet glycoprotein IIb/IIIa inhibitors abciximab versus tirofiban during coronary intervention
Q33934090	Efficacy and safety of abciximab in diabetic patients who underwent percutaneous coronary intervention with thienopyridines loading: a meta-analysis
Q33345884	Efficacy and safety of minimal dose (< or =1,000 units) unfractionated heparin with abciximab in percutaneous coronary intervention
Q37599605	Efficacy and safety of tirofiban-supported primary percutaneous coronary intervention in patients pretreated with 600 mg clopidogrel: results of propensity analysis using the Clinical Center of Serbia STEMI Register
Q39510746	Efficacy of abciximab induced platelet blockade using a rapid point of care assay
Q33331867	Efficacy of abciximab readministration in coronary intervention.
Q40780278	Emergency coronary artery bypass graft surgery in abciximab-treated patients
Q33663306	Emerging treatment of acute coronary syndromes with platelet glycoprotein IIB/IIIA inhibitors
Q33181414	Endovascular brachytherapy in coronary arteries: the Rotterdam experience
Q28301431	Enoxaparin in acute coronary syndromes
Q40732057	Eptifibatide: a potent inhibitor of the platelet receptor integrin, glycoprotein IIb/IIIa
Q33328451	Eptifibatide: a review of its use in patients with acute coronary syndromes and/or undergoing percutaneous coronary intervention
Q35129386	Evaluation of Glycoprotein IIb/IIIa Inhibitors in Carotid Angioplasty and Stenting
Q28213564	Evaluation of bleeding complications associated with glycoprotein IIb/IIIa inhibitors
Q56945087	Evolution of improved antithrombotic and antiplatelet agents: genesis of the comparison of abciximab complications with hirulog [and back-up abciximab] events trial (CACHET)
Q58088660	Experience is important; progress makes the difference!
Q34684081	Experience with glycoprotein IIb/IIIa antagonists in patients with acute coronary syndromes
Q34069676	Facilitated percutaneous coronary intervention for acute myocardial infarction
Q28209720	Facilitating optimal care of acute coronary, cerebrovascular and peripheral vascular syndromes in the emergency department: the role of oral antiplatelet therapy
Q58088799	Failure to monitor ticlopidine: the case for clopidogrel
Q33331255	Fatal cerebral hemorrhage and severe thrombocytopenia during abciximab treatment
Q45099923	Fibrinogen receptor antagonists induce conformational changes of the human platelet glycoprotein IIb.
Q34271300	Fibrinogen: structure, function, and surface interactions
Q34868156	Fibrinolytic and mechanical intervention trials in ST elevation acute myocardial infarction.
Q64934723	From Snake Venom's Disintegrins and C-Type Lectins to Anti-Platelet Drugs.
Q41737288	Fundamentals of coagulation and glycoprotein IIb/IIIa receptor inhibition
Q33735581	Future directions in thrombolysis.
Q33685127	GPIIbIIIa inhibitors as adjunctive therapy in acute myocardial infarction
Q34953097	Gene therapy to promote thromboresistance: local overexpression of tissue plasminogen activator to prevent arterial thrombosis in an in vivo rabbit model
Q28184207	General pharmacologic treatment of acute myocardial infarction
Q35008537	Glicoprotein (GP) IIb/IIIa inhibitors for acute stroke treatment
Q34180931	Glycoprotein IIb/IIIa Inhibition as an adjunct to rescue angioplasty after failed fibrinolysis
Q35583996	Glycoprotein IIb/IIIa Receptor Antagonists in the Treatment of Acute ST Elevation MI: From Hypotheses to Unexpected Recent Observations
Q50970072	Glycoprotein IIb/IIIa antagonists during carotid artery stenting: results from the carotid artery stenting (CAS) registry of the Arbeitsgemeinschaft Leitende Kardiologische Krankenhausärzte (ALKK).
Q35088072	Glycoprotein IIb/IIIa inhibition in early intent-to-stent treatment of acute coronary syndromes: EPISTENT, ADMIRAL, CADILLAC, and TARGET.
Q33336709	Glycoprotein IIb/IIIa inhibitors and low-molecular-weight heparins: a combined role in coronary interventions?
Q36053248	Glycoprotein IIb/IIIa inhibitors in patients with end-stage renal disease
Q44295154	Glycoprotein IIb/IIIa inhibitors in unstable angina
Q38549613	Glycoprotein IIb/IIIa inhibitors: The resurgence of tirofiban
Q43679047	Glycoprotein IIb/IIIa inhibitors: more different than alike?
Q35924051	Glycoprotein IIb/IIIa receptor antagonists and risk of bleeding: a single-center experience in 1020 patients
Q33330501	Glycoprotein IIb/IIIa receptor antagonists in non-ST elevation acute coronary syndromes and percutaneous revascularisation: a review of trial reports
Q36358900	Glycoprotein IIb/IIIa receptor antagonists: a review of the pivotal trials
Q33742233	Glycoprotein IIb/IIIa receptor antagonists: clinical pharmacology in cardiovascular diseases of aging
Q33664582	Glycoprotein IIb/IIIa receptor inhibition in interventional cardiology
Q34126038	Glycoprotein IIb/IIIa receptor inhibitors in acute coronary syndromes: conquests and new challenges
Q35139249	Glycoprotein IIb/IIIa receptor inhibitors in percutaneous coronary intervention and acute coronary syndrome
Q34185265	Glycoprotein IIb/IIIa receptor therapy in percutaneous coronary intervention and non-ST-segment elevation acute coronary syndromes. Estimating the economic implications
Q28193156	Glycoprotein receptor inhibitors in the management of acute coronary syndromes
Q28239975	Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology
Q33846408	Guidelines for the diagnosis and management of unstable angina and non-Q-wave myocardial infarction: proposed revisions. International Cardiology Forum
Q46125254	HORIZONS trial: a step forward for primary percutaneous coronary intervention
Q78106205	Heparin after percutaneous intervention (HAPI): a prospective multicenter randomized trial of three heparin regimens after successful coronary intervention
Q28192448	Heparin and coumadin versus acetylsalicylic acid for prevention of restenosis after coronary angioplasty
Q34858594	Heparin dose during percutaneous coronary intervention: how low dare we go?
Q33504198	Heparin dosing in patients undergoing coronary intervention
Q33394179	Heparin in interventional radiology: a therapy in evolution
Q38337424	Heparin is Not Inferior to Bivalirudin in Percutaneous Coronary Intervention-Focusing on the Effect of Glycoprotein IIb/IIIa Inhibitor Use: A Meta-Analysis
Q36415289	High Bolus Tirofiban vs Abciximab in Acute STEMI Patients Undergoing Primary PCI - The Tamip Study
Q40784800	High platelet count in platelet-rich plasma reduces measured platelet inhibition by abciximab but not tirofiban nor eptifibatide glycoprotein IIb/IIIa receptor antagonists
Q33577110	Hospital percutaneous coronary intervention volume and patient mortality, 1998 to 2000: does the evidence support current procedure volume minimums?
Q73740288	IIb's are not IIb's
Q73583538	Immediate and long-term outcome of intracoronary stent implantation for true bifurcation lesions
Q33334485	Immediate coronary artery bypass surgery after platelet inhibition with eptifibatide: results from PURSUIT. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrelin Therapy
Q44060764	Immediate protamine administration and sheath removal following percutaneous coronary intervention: a prospective study of 429 patients
Q44985681	Impact of abciximab in elderly patients with high-risk acute coronary syndrome undergoing percutaneous coronary intervention: an observational registry study
Q56944577	Impact of body mass index on outcome after percutaneous coronary intervention (the obesity paradox)
Q41589803	Impact of eptifibatide on early ischemic events in acute ischemic coronary syndromes: a review of the IMPACT II trial. Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis
Q50763806	Impact of platelet glycoprotein IIb/IIIa inhibitor therapy on in-hospital outcomes and long-term survival following percutaneous coronary rotational atherectomy.
Q35581688	Impact of preprocedural white blood cell count on long term mortality after percutaneous coronary intervention: insights from the EPIC, EPILOG, and EPISTENT trials
Q51201074	Impacts of glycoprotein IIb/IIIa inhibition on QT dispersion after successful percutaneous coronary intervention.
Q33743233	Implications of the Organization to Assess Strategies for Ischemic Syndromes-2 (OASIS-2) study and the results in the context of other trials.
Q30471377	Improved clinical outcome after invasive management of patients with recent myocardial infarction and proven myocardial viability: primary results of a randomized controlled trial (VIAMI-trial).
Q74315434	Improving outcome over time of percutaneous coronary interventions in unstable angina
Q74062358	In vivo demonstration of an antithrombin effect of abciximab
Q84218678	In-hospital outcomes after elective and non-elective percutaneous coronary interventions in hospitals with and without on-site cardiac surgery backup
Q58088768	In-hospital resource utilization in coronary angioplasty: the impact of increased coronary stenting rates and antiplatelet therapy
Q31438049	Incidence of intracranial hemorrhage complicating treatment with glycoprotein IIb/IIIa receptor inhibitors: a pooled analysis of major clinical trials
Q33735570	Incorporating platelet glycoprotein IIb/IIIa inhibition in critical pathways: unstable angina/non-ST-segment elevation myocardial infarction.
Q73574905	Increased platelet reactivity in patients given orbofiban after an acute coronary syndrome: an OPUS-TIMI 16 substudy. Orbofiban in Patients with Unstable coronary syndromes. Thrombolysis In Myocardial Infarction
Q77156276	Influence of coronary thrombus on outcome of percutaneous coronary angioplasty in the current era (the Mayo Clinic experience)
Q74187728	Inhibition of platelet-dependent prothrombinase activity and thrombin generation by glycoprotein IIb/IIIa receptor-directed antagonists: potential contributing mechanism of benefit in acute coronary syndromes
Q73870590	Initial results, predictors of success, and long-term outcome of primary coronary angioplasty for acute myocardial infarction in a community hospital
Q33671965	Interesting cases from the University of Texas Medical Branch
Q58250248	Intermediate coronary artery stenosis: evidence-based decisions in interventions to avoid the oculostenotic reflex
Q28193761	Interventional therapy for coronary artery disease
Q33635835	Interventional therapy is the best approach for acute coronary syndromes
Q73293602	Intracellular trafficking of the alphaIIbbeta3 receptor antagonist, abciximab, in normal and Glanzmann's disease megakaryocytes
Q37138914	Intracoronary abciximab use in patients undergoing PCI at a community hospital: a single operator experience
Q36557600	Intracoronary administration of abciximab during percutaneous coronary interventions: should this be the routine and preferred approach?
Q51176352	Intracoronary bolus administration of eptifibatide during percutaneous coronary stenting for non ST elevation myocardial infarction and unstable angina.
Q84997891	Intracoronary delivery of eptifibatide with the ClearWay® RX infusion catheter
Q73137697	Intracranial deployment of coronary stents for symptomatic atherosclerotic disease
Q44699573	Intracranial hemorrhage following neuroendovascular procedures with abciximab is associated with high mortality: a multicenter series.
Q53351474	Invasive versus conservative strategies in unstable angina and non-Q-wave myocardial infarction following treatment with tirofiban: rationale and study design of the international TACTICS-TIMI 18 Trial. Treat Angina with Aggrastat and determine Cost
Q34599970	Ipsilateral intracerebral hemorrhage following carotid stent-assisted angioplasty: a manifestation of hyperperfusion syndrome--a case report
Q44158698	Is glycoprotein IIb/IIIa antagonism as effective in women as in men following percutaneous coronary intervention?. Lessons from the ESPRIT study
Q35691998	Is the use of unfractionated heparin in acute coronary syndrome outmoded?
Q34051300	Ischemic complications after percutaneous transluminal coronary angioplasty
Q37070767	Issues in management of acute coronary syndromes: effects of bleeding.
Q30633025	Laser angioplasty of restenosed coronary stents: results of a multicenter surveillance trial. The Laser Angioplasty of Restenosed Stents (LARS) Investigators
Q52143012	Learning from the recently completed oral glycoprotein IIb/IIIa receptor antagonist trials.
Q37679719	Limitations of current therapies to prevent thrombosis: a need for novel strategies
Q74551380	Long-term administration of glycoprotein IIb/IIIa antagonists
Q35937178	Long-term clinical benefits of a platelet glycoprotein IIb/IIIa receptor blocker, abciximab (ReoPro), in high-risk diabetic patients undergoing percutaneous coronary intervention
Q73662493	Long-term clinical events following creatine kinase--myocardial band isoenzyme elevation after successful coronary stenting
Q56944701	Long-term mortality benefit with abciximab in patients undergoing percutaneous coronary intervention
Q56944585	Long-term mortality benefit with the combination of stents and abciximab for cardiogenic shock complicating acute myocardial infarction
Q52208202	Long-term oral platelet glycoprotein IIb/IIIa receptor antagonism with sibrafiban after acute coronary syndromes: study design of the sibrafiban versus aspirin to yield maximum protection from ischemic heart events post-acute coronary syndromes (SYM
Q42799914	Long-term results following switch from abciximab to eptifibatide during percutaneous coronary intervention.
Q77530104	Long-term results of RITA-1 trial: clinical and cost comparisons of coronary angioplasty and coronary-artery bypass grafting. Randomised Intervention Treatment of Angina
Q35562127	Loss of bone marrow-derived vascular progenitor cells leads to inflammation and atherosclerosis
Q34075194	Lotrafiban: an oral platelet glycoprotein IIb/IIIa blocker
Q28193196	Low molecular weight heparins and glycoprotein IIb/IIIa antagonists
Q33699831	Low-dose fibrinolytics and glycoprotein IIb/IIIa receptor blockade for the treatment of acute myocardial infarction
Q36022983	Low-molecular-weight heparin for the treatment of venous thromboembolism in the elderly
Q35733959	Low-molecular-weight heparins in the cardiac catheterization laboratory
Q35546867	Low‐molecular‐weight heparin during percutaneous coronary interventions: Rationale, results, and recommendations
Q30305538	Management of Acute Ischemic Coronary Syndromes: The Present and Future
Q37223676	Management of acute coronary syndrome
Q28201103	Management of antiplatelet therapy for minimization of bleeding risk before cardiac surgery
Q77958189	Management of arterial puncture site after catheterization procedures: evaluating a suture-mediated closure device
Q33671970	Management of high-risk subsets in unstable angina
Q40858772	Management strategies for a better outcome in unstable coronary artery disease
Q74224807	Massive pulmonary hemorrhage in a patient treated with a platelet glycoprotein IIb/IIIa inhibitor
Q34453226	Mechanisms of angioplasty and stent restenosis: implications for design of rational therapy
Q33637663	Mechanisms of antithrombotic drugs
Q36084505	Medical decision making with incomplete evidence--choosing a platelet glycoprotein IIbIIIa receptor inhibitor for percutaneous coronary interventions
Q34084217	Medical therapy of unstable angina and non-Q-wave myocardial infarction
Q33376977	Meta-analysis of clinical efficacy and bleeding risk with intravenous glycoprotein IIb/IIIa antagonists for percutaneous coronary intervention
Q32076730	Meta-analysis of effectiveness and safety of abciximab versus eptifibatide or tirofiban in percutaneous coronary intervention
Q56944438	Meta-analysis of survival with platelet glycoprotein IIb/IIIa antagonists for percutaneous coronary interventions
Q48260079	Middle cerebral artery stenting for acute ischemic stroke after unsuccessful Merci retrieval
Q50882400	Modifiable risk factors for vascular access site complications in the IMPACT II Trial of angioplasty with versus without eptifibatide. Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis.
Q35847529	Modulating thrombotic potential in catheter-based percutaneous coronary and peripheral vascular interventions
Q47761313	Molecular identification of the cross-reacting epitope on alphaM beta2 integrin I domain recognized by anti-alphaIIb beta3 monoclonal antibody 7E3 and its involvement in leukocyte adherence
Q37608580	Monitoring antiplatelet therapy with point-of-care platelet function assays: a review of the evidence
Q34675287	Monitoring of platelet function in the setting of glycoprotein IIb/IIIa inhibitor therapy
Q36478827	Monoclonal antibodies as targeting and therapeutic agents: prospects for liver transplantation, hepatitis and hepatocellular carcinoma.
Q34236658	Monoclonal antibody therapy
Q47439457	Mortality benefit of beta blockade in patients with acute coronary syndromes undergoing coronary intervention: pooled results from the Epic, Epilog, Epistent, Capture and Rapport Trials
Q44346890	Multi-year follow-up of abciximab therapy in three randomized, placebo-controlled trials of percutaneous coronary revascularization
Q51471544	Near-site monitoring of the antiplatelet drug abciximab using the Hemodyne analyzer and modified thrombelastograph.
Q74551407	New antiplatelet agents for acute coronary syndromes
Q41711755	New antiplatelet drugs
Q77397128	New antithrombotic agents
Q34306764	New developments in percutaneous coronary intervention
Q28184399	New heparin dosing recommendations for patients with acute coronary syndromes
Q33655209	New thrombolytics, anticoagulants, and platelet antagonists: the future of clinical practice
Q33838920	Newer antithrombotic strategies in the initial management of non-ST-segment elevation acute coronary syndromes
Q36634214	Newer pharmacotherapy in patients undergoing percutaneous coronary interventions: a guide for pharmacists and other health care professionals
Q31080288	Nitinol versus stainless steel stents: acute thrombogenicity study in an ex vivo porcine model.
Q34926982	Noncoronary complications of coronary intervention
Q41615853	Nonimmunogenicity of eptifibatide, a cyclic heptapeptide inhibitor of platelet glycoprotein IIb-IIIa
Q34075160	Novel approaches for the prevention of restenosis
Q73365339	Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial
Q33333176	Occurrence and clinical significance of pseudothrombocytopenia during abciximab therapy
Q33503354	Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization. Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) Study Group
Q50763029	Ongoing clinical trials of anti-platelet agents in the management of acute ischaemic coronary syndromes.
Q42595003	Open-label, sequential comparison of eptifibatide with abciximab for patients undergoing percutaneous coronary intervention
Q37943829	Optimal use of platelet glycoprotein IIb/IIIa receptor antagonists in patients undergoing percutaneous coronary interventions
Q34113324	Optimizing antiplatelet therapy in coronary interventions.
Q34712338	Optimizing glycoprotein IIb/IIIa inhibition: lessons from recent randomized controlled trials
Q35575676	Optimizing glycoprotein IIb/IIIa receptor antagonist use for the non-ST–segment elevation acute coronary syndromes: risk stratification and therapeutic intervention
Q28186918	Oral glycoprotein IIb/IIIa antagonism in patients with coronary artery disease
Q34045971	Oral glycoprotein IIb/IIIa antagonists: new insights from the SYMPHONY trial
Q34377015	Oral glycoprotein IIb/IIa antagonists for unstable angina--is there still a chance for the oral substances?
Q74551376	Oral inhibitors of platelet membrane receptor glycoprotein IIb/IIIa in clinical cardiology: issues and opportunities
Q35199720	Oral platelet glycoprotein IIb/IIIa receptor inhibitors--Part I.
Q33504480	Orgaran during rotational atherectomy in the setting of heparin-induced thrombocytopenia
Q37397095	Outcome and Predictors of Stent Thrombosis in the First Romanian Registry of Drug Eluting Stent (RODESINO EXTENSION)
Q35773301	Outcome of percutaneous coronary intervention in hospitals with and without on-site cardiac surgery standby
Q44604851	Outcome of urgent and elective percutaneous coronary interventions after pharmacologic reperfusion with tenecteplase combined with unfractionated heparin, enoxaparin, or abciximab
Q33367950	Outcomes and costs of abciximab versus eptifibatide for percutaneous coronary intervention
Q56928579	Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial
Q44145226	Outcomes at 6 months for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularisation with stent placement: the TARGET follow-up study
Q43524250	Outcomes following Bail-Out abciximab administration during primary intervention in acute myocardial infarction (The CADILLAC Trial)
Q35547240	Outcomes with Changes in Prescribing of Glycoprotein IIb/IIIa Inhibitors in PCI
Q33768927	Overcoming thrombolytic resistance: rationale and initial clinical experience combining thrombolytic therapy and glycoprotein IIb/IIIa receptor inhibition for acute myocardial infarction
Q47816474	PIa1/a2 polymorphism of glycoprotein IIIa and risk of coronary artery disease and restenosis following coronary angioplasty
Q33399576	Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
Q32108552	Pathophysiology and therapeutic concepts in coronary restenosis
Q34001532	Pathophysiology and therapeutic modification of thrombin generation in patients with coronary artery disease
Q36867295	Percutaneous coronary intervention and the no-reflow phenomenon.
Q36752079	Percutaneous coronary intervention for left main coronary artery disease
Q73782440	Percutaneous coronary intervention in octogenarians and the safety of glycoprotein IIb/IIIa inhibitors
Q78503399	Percutaneous coronary intervention versus coronary bypass graft surgery for diabetic patients with unstable angina and risk factors for adverse outcomes with bypass: outcome of diabetic patients in the AWESOME randomized trial and registry
Q37900509	Percutaneous coronary interventions in facilities without cardiac surgery on site
Q73734749	Percutaneous coronary interventions in patients with renal insufficiency: a high-risk, under-studied cohort
Q74805430	Percutaneous intervention: design, technique, and pharmacology
Q45118831	Percutaneous transluminal coronary angioplasty versus thrombolysis in acute myocardial infarction
Q35020325	Percutaneous treatment for carotid stenosis
Q34147112	Peri-procedural myocardial injury during percutaneous coronary intervention: an important target for cardioprotection.
Q36263844	Peri-procedural myocardial injury: 2005 update
Q33591378	Periprocedural creatine kinase-MB elevations: long-term impact and clinical implications
Q34581514	Pharmaceutical thrombosis prevention in cardiovascular disease
Q28189075	Pharmacodynamic characterization of the interaction between abciximab or tirofiban with unfractionated or a low molecular weight heparin in healthy subjects
Q28199325	Pharmacodynamic characterization of the interaction between the glycoprotein IIb/IIIa inhibitor YM337 and unfractionated heparin and aspirin in humans
Q40451233	Pharmacodynamic enhancement of the anti-platelet antibody fab abciximab by site-specific pegylation.
Q34180945	Pharmacokinetics and pharmacodynamics of low-molecular-weight heparins and glycoprotein IIb/IIIa receptor antagonists in renal failure
Q73779375	Pharmacokinetics and pharmacodynamics of sibrafiban, an orally administered GP IIb/IIIa antagonist, following coadministration of aspirin and heparin
Q36787291	Pharmacological antithrombotic adjuncts to percutaneous coronary intervention
Q37638256	Pharmacological prevention of peri-, and post-procedural myocardial injury in percutaneous coronary intervention
Q28193946	Pharmacological treatment of elderly patients with acute coronary syndromes without persistent ST segment elevation
Q33342507	Pharmacology and clinical use of bivalirudin
Q34768517	Pharmacotherapeutic options for the management of myocardial infarction
Q74012794	PlA polymorphism of glycoprotein IIIa and risk of adverse events after coronary stent placement
Q38547727	Platelet GP IIb-IIIa Receptor Antagonists in Primary Angioplasty: Back to the Future
Q56944972	Platelet GPIIb-IIIa blockers
Q73681288	Platelet Inhibition in Cardiovascular Disease Management: Aspirin and Beyond
Q33704606	Platelet PlA2 polymorphism and thromboembolic events: from inherited risk to pharmacogenetics
Q35821899	Platelet activation in myocardial ischemic syndromes
Q33951293	Platelet adhesion receptors: novel targets for anti-thrombotic therapy
Q34282877	Platelet aggregation inhibition with glycoprotein IIb--IIIa inhibitors
Q28192464	Platelet aggregation inhibitors for use in peripheral vascular interventions: what can we learn from the experience in the coronary arteries?
Q35001049	Platelet glycoprotein IIb/IIIa antagonists in clinical trials for the treatment of coronary artery disease
Q56944855	Platelet glycoprotein IIb/IIIa blockade and outcome of cardiogenic shock complicating acute coronary syndromes without persistent ST-segment elevation
Q24202522	Platelet glycoprotein IIb/IIIa blockers during percutaneous coronary intervention and as the initial medical treatment of non-ST segment elevation acute coronary syndromes
Q24202999	Platelet glycoprotein IIb/IIIa blockers during percutaneous coronary intervention and as the initial medical treatment of non-ST segment elevation acute coronary syndromes
Q24235385	Platelet glycoprotein IIb/IIIa blockers during percutaneous coronary intervention and as the initial medical treatment of non-ST segment elevation acute coronary syndromes
Q28191096	Platelet glycoprotein IIb/IIIa blockers for percutaneous coronary revascularization, and unstable angina and non-ST-segment elevation myocardial infarction
Q33334039	Platelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes
Q34180960	Platelet glycoprotein IIb/IIIa inhibitors combined with fibrinolytic agents to treat acute myocardial infarction
Q34336824	Platelet glycoprotein IIb/IIIa inhibitors for acute coronary syndromes: initiate treatment early or wait for the catheterization laboratory?
Q56944618	Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials
Q33336362	Platelet glycoprotein IIb/IIIa receptor antagonists
Q31934867	Platelet glycoprotein IIb/IIIa receptor antagonists and coronary artery disease
Q33914229	Platelet glycoprotein IIb/IIIa receptor antagonists and their use in elderly patients
Q33826201	Platelet glycoprotein IIb/IIIa receptor antagonists: current concepts and future directions
Q78726597	Platelet glycoprotein IIb/IIIa receptor blockade and coronary resistance in unstable angina
Q24793321	Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease
Q33887755	Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease.
Q47816484	Platelet glycoprotein IIb/IIIa receptor blockade with abciximab reduces ischemic complications in patients undergoing directional coronary atherectomy. EPILOG Investigators. Evaluation of PTCA to Improve Long-term Outcome by c7E3 GP IIb/IIIa Recepto
Q34370505	Platelet glycoprotein IIb/IIIa-receptor inhibitors in patients with acute coronary syndromes or undergoing percutaneous coronary interventions: a review
Q34027408	Platelet glycoprotein receptor site blockade in coronary artery disease
Q43818628	Platelet hemostasis capacity in smokers. In vitro function analyses with 3.2% citrated whole blood
Q37658732	Platelet hyperfunction as risk factor for chronic and acute coronary events
Q44068988	Platelet inhibition with tirofiban early during percutaneous coronary intervention: dosing revisited
Q28219354	Platelet inhibitors in non-ST-segment elevation acute coronary syndromes and percutaneous coronary intervention: glycoprotein IIb/IIIa inhibitors, clopidogrel, or both?
Q33635802	Platelet-dependent and procoagulant mechanisms in arterial thrombosis.
Q33770499	Platelet-endothelial interactions in atherothrombotic disease: therapeutic implications.
Q33862443	Platelets and restenosis
Q28194426	Platelets: is aspirin sufficient or must we know how to pronounce abciximab?
Q35197086	Polyethylene glycol diisocyanate decreases platelet deposition after balloon injury of rabbit femoral arteries
Q43920519	Potential anaphylactic shock with abciximab readministration
Q34061211	Potential future clinical applications for the GPIIb/IIIa antagonist, abciximab in thrombosis, vascular and oncological indications
Q73740291	Potential role of abciximab in ischemic cerebrovascular disease
Q28190541	Potential use of a low-molecular-weight heparin to prevent restenosis in patients with extensive wall damage following peripheral angioplasty
Q30978021	Power thrombectomy in acute ischemic coronary syndromes
Q73186321	Practice guidelines of the Spanish Society of Cardiology. Recommendations for the use of antithrombotic treatment in cardiology
Q47847825	Predicting vascular complications in percutaneous coronary interventions
Q41735567	Predictive value of C-reactive protein and troponin T in patients with unstable angina: a comparative analysis. CAPTURE Investigators. Chimeric c7E3 AntiPlatelet Therapy in Unstable angina REfractory to standard treatment trial
Q74187737	Predictors of bleeding complications after rescue coronary interventions
Q28191487	Predictors of long-term outcomes following direct percutaneous coronary intervention for acute myocardial infarction
Q41743553	Preferential benefit of platelet glycoprotein IIb/IIIa receptor blockade: specific considerations by device and disease state
Q58230324	Preprocedural serum levels of C-reactive protein predict early complications and late restenosis after coronary angioplasty
Q36815950	Present and evolving role of eptifibatide in the treatment of acute coronary syndromes
Q33931454	Prevention and treatment of thromboembolic and ischemic complications associated with endovascular procedures: Part I--Pathophysiological and pharmacological features
Q37801291	Prevention of the renarrowing of coronary arteries using drug-eluting stents in the perioperative period: an update.
Q33500264	Primary and secondary safety endpoints from IMPACT II. Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis
Q33699864	Primary stenting and glycoprotein IIb/IIIa inhibitors in acute myocardial infarction
Q73453215	Procedural results and intermediate clinical outcomes after multiple saphenous vein graft stenting
Q77612978	Procedural results and long-term clinical outcomes following coronary stenting in perimyocardial infarction syndromes
Q33635812	Procoagulant activity during coronary interventions and coronary artery patency
Q33366275	Profound thrombocytopenia associated with tirofiban: case report and review of literature
Q44471766	Prognostic implication of creatine kinase release after elective percutaneous coronary intervention in the pre-IIb/IIIa antagonist era.
Q44440230	Prolonged systemic delivery of tirofiban in a thrombus-laden saphenous vein graft
Q40833806	Prospective use of glycoprotein IIb/IIIa receptor blockers in the emergency department setting
Q64976844	Rails, ReoPro, and the real world.
Q56945137	Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade
Q41737297	Rationale and clinical evidence for the use of GP IIb/IIIa inhibitors in acute coronary syndromes
Q36679440	Rationale for intracoronary administration of abciximab
Q35803300	Recent advances in the management of unstable angina and non-Q-wave myocardial infarction
Q41744467	Recent advances. Cardiology
Q40829771	Recent antiplatelet drug trials in the acute coronary syndromes. Clinical interpretation of PRISM, PRISM-PLUS, PARAGON A and PURSUIT.
Q35582491	Recommendations on percutaneous coronary intervention for the reperfusion of acute ST elevation myocardial infarction
Q33370280	Recurrent acute profound thrombocytopenia related to readministration of eptifibatide
Q53657210	Recurrent stent thrombosis associated with lupus anticoagulant due to renal cell carcinoma.
Q34074021	Redefining medical treatment in the management of unstable angina
Q56945162	Reduction in the need for unplanned stenting with the use of platelet glycoprotein IIb/IIIa blockade in percutaneous coronary intervention
Q30322132	Reduction of restenosis by vessel size adapted percutaneous transluminal coronary angioplasty using intravascular ultrasound.
Q88842600	Regulation of Platelet Activation and Coagulation and Its Role in Vascular Injury and Arterial Thrombosis
Q44318754	Regulation of clot retraction by glycoprotein IIb/IIIa antagonists.
Q54117515	Relation between abrupt vessel closure and the anticoagulant response to heparin or bivalirudin during coronary angioplasty.
Q51842734	Relation between the degree of procedural anticoagulation and complications after coronary stent implantation.
Q56944638	Relation of platelet inactivation with intravenous glycoprotein IIb/IIIa antagonists to major bleeding (from the GOLD study)
Q44307919	Relationship between heparin anticoagulation and clinical outcomes in coronary stent intervention: observations from the ESPRIT trial
Q28185728	Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial
Q33414147	Reprint of "Decline in platelet count and long-term post-PCI ischemic events: implication of the intra-aortic balloon pump".
Q39446390	Restoration of coronary blood flow by single bolus injection of the GPIIb/IIIa receptor antagonist c7E3 Fab in a patient with acute myocardial infarction of recent onset.
Q38006947	Review of Currently Available GP IIb/IIIa Inhibitors and Their Role in Peripheral Vascular Interventions
Q78016569	Rheolytic thrombectomy with Angiojet in thrombus-containing lesions
Q54157255	Rheolytic thrombectomy: a new treatment for stent thrombosis.
Q77361734	Risk assessment of slow or no-reflow phenomenon in aortocoronary vein graft percutaneous intervention
Q33434702	Risk of thrombocytopenia with glycoprotein IIb/IIIa inhibitors across drugs and patient populations: a meta-analysis of 29 large placebo-controlled randomized trials
Q34445660	Risk stratification in non-ST segment elevation acute coronary syndromes with special focus on recent guidelines.
Q35944733	Role of low-molecular-weight heparin in invasive management of non-ST-elevation acute coronary syndromes
Q26471900	Routine invasive strategies versus selective invasive strategies for unstable angina and non-ST elevation myocardial infarction in the stent era
Q47808971	Routine use of abciximab in coronary stenting?
Q74434392	Safe use of platelet GP IIb/IIIa inhibitors
Q33715389	Safety and efficacy of abciximab as an adjunct to percutaneous coronary intervention
Q74600246	Safety and efficacy of suture-mediated closure after percutaneous coronary interventions
Q58283607	Safety and efficacy of treatment with platelet GPIIb/IIIa receptor blockade in unstable angina patients awaiting PTCA at a referring clinic
Q33391065	Safety evaluation of tirofiban
Q28186167	Safety of abciximab administration during PCI of patients with previous stroke
Q33342386	Safety of abciximab during percutaneous coronary intervention in patients with chronic renal insufficiency
Q44468433	Safety of abciximab in patients with chronic renal insufficiency who are undergoing percutaneous coronary interventions
Q44304792	Safety of concomitant therapy with eptifibatide and enoxaparin in patients undergoing percutaneous coronary intervention: results of the Coronary Revascularization Using Integrilin and Single bolus Enoxaparin Study
Q37178035	Safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention
Q34242912	Safety of immediate reversal of anticoagulation by protamine to reduce bleeding complications after infarct artery stenting for acute myocardial infarction and adjunctive abciximab therapy
Q79177258	Safety of same-day–discharge radial percutaneous coronary intervention: a retrospective study
Q28193251	Safety profile and tolerability of intravenous AR-C69931MX, a new antiplatelet drug, in unstable angina pectoris and non-Q-wave myocardial infarction
Q43228654	Salvage angioplasty following failed thrombolysis
Q30438893	Selecting the optimal antithrombotic regimen for patients with acute coronary syndromes undergoing percutaneous coronary intervention
Q33336702	Severe delayed thrombocytopenia associated with abciximab (ReoPro) therapy
Q33338960	Severe thrombocytopenia possibly related to readministration of eptifibatide
Q64252943	Shedding New Light on The Role of ανβ3 and α5β1 Integrins in Rheumatoid Arthritis
Q43751094	Short-term comparative outcomes associated with the use of GP IIb/IIIa antagonists in patients undergoing coronary intervention
Q73234405	Simultaneous quantification of seven active metabolites of roxifiban in human plasma by LC/MS/MS in the presence of an interfering displacer at millimolar concentrations
Q28195841	Single high-dose bolus tirofiban with high-loading-dose clopidogrel in primary coronary angioplasty
Q47822603	Six-month angiographic and clinical follow-up of patients prospectively randomized to receive either tirofiban or placebo during angioplasty in the RESTORE trial. Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis.
Q34107084	Small-molecule glycoprotein IIb/IIIa inhibitors as adjunctive therapy in percutaneous coronary interventions
Q36324876	Some issues with composite endpoints in clinical trials
Q44161861	Stent deployment with distal vascular protection for the culprit vein graft stenosis in a patient with an acute infarct and cardiogenic shock
Q30312070	Stent restenosis and the use of drug-eluting stents in patients with diabetes mellitus
Q58131798	Stent-Assisted Coil Embolization Using Only a Glycoprotein IIb/IIIa Inhibitor (Tirofiban) for Ruptured Wide-Necked Aneurysm Repair
Q43897742	Suboptimal early inhibition of platelets by treatment with tirofiban and implications for coronary interventions
Q45882558	Synergistic effect of thrombus aspiration and abciximab in primary percutaneous coronary intervention
Q74099001	Synergy between intracoronary stenting and abciximab in improving angiographic and clinical outcomes of primary angioplasty in acute myocardial infarction
Q24805625	Systematic adjudication of myocardial infarction end-points in an international clinical trial
Q33417854	Targeting integrin and integrin signaling in treating thrombosis
Q51789531	Technological advances in the design of catheters and devices used in renal artery interventions: impact on complications.
Q51179484	Temporal trends in major angioplasty complications: technical issues and the case for on-site coronary surgery.
Q50468599	Temporal trends, safety, and efficacy of bivalirudin in elective percutaneous coronary intervention: insights from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium.
Q33381441	The GPIIb/IIIa (integrin alphaIIbbeta3) odyssey: a technology-driven saga of a receptor with twists, turns, and even a bend
Q33572281	The Optimal Route of Administration of the Glycoprotein IIb/IIIa Receptor Antagonist Abciximab During Percutaneous Coronary Intervention; Intravenous Versus Intracoronary
Q28165987	The Role of Enoxaparin in Interventional Management of Patients with Acute Coronary Syndromes
Q56944889	The benefit of abciximab in percutaneous coronary revascularization is not device-specific
Q37070776	The challenge of defining bleeding among patients with acute coronary syndromes
Q34306790	The contemporary management of acute myocardial infarction
Q34746674	The development of interventional cardiology
Q56945181	The duration of pretreatment with ticlopidine prior to stenting is associated with the risk of procedure-related non–Q-wave myocardial infarctions
Q34510678	The effects of platelet inhibitors on blood use in cardiac surgery
Q36614135	The evolving role of glycoprotein IIb/IIIa inhibitor therapy in contemporary care of acute coronary syndrome patients
Q33689211	The evolving role of platelet glycoprotein IIb/IIIa inhibitors in the management of acute coronary syndromes
Q77151290	The extracellular matrix in balloon arterial injury: a novel target for restenosis prevention
Q40815302	The future of minimally invasive myocardial revascularization: a cardiologist's view
Q61663372	The influence of abciximab use on clinical outcome after aortocoronary vein graft interventions
Q35936923	The long-term clinical results of a platelet glycoprotein IIb/IIIa receptor blocker (Abciximab: Reopro) coated stent in patients with coronary artery disease
Q73275560	The no-reflow phenomenon: a light at the end of the tunnel?
Q43826064	The platelet function dose-response to abciximab during percutaneous coronary revascularization is variable
Q33641457	The platelet in acute coronary syndromes: defining the pivotal role of platelet glycoprotein IIb/IIIa receptor blockade
Q30850777	The practical clinical guidelines of the Sociedad Española de Cardiología on interventional cardiology: coronary angioplasty and other technics
Q44297618	The prevention of minor myocardial injury with ticlopidine pretreatment in patients undergoing elective coronary stenting
Q47865545	The relation between preprocedural C-reactive protein levels and early and late complications in patients with acute myocardial infarction undergoing interventional coronary angioplasty.
Q56945012	The relationship between periprocedural myocardial infarction and subsequent target vessel revascularization following percutaneous coronary revascularization
Q28176548	The role of antiplatelet therapy in the management of acute coronary syndromes
Q73599503	The role of clinical nonfatal end points in cardiovascular phase II/III clinical trials
Q28165466	The role of clopidogrel in the management of acute coronary syndromes
Q33809060	The role of coronary angioplasty and stenting in acute myocardial infarction
Q33347022	The role of low-molecular-weight heparin in the management of acute coronary syndromes
Q34282896	The role of low-molecular-weight heparins in the management of unstable angina and non-ST-segment elevation myocardial infarction
Q34674157	The role of pharmacotherapy and catheter-based intervention in the management of patients with non-ST-segment elevation acute coronary syndromes
Q48125259	The safety and efficacy of the Angio-Seal closure device in diagnostic and interventional neuroangiography setting: a single-center experience with 1,443 closures
Q33367036	The therapeutic use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes
Q35080401	The use of adjunctive GPIIb/IIIa inhibitors in patients with unstable angina/non-Q-wave MI undergoing percutaneous coronary intervention
Q28186375	The use of antiplatelet agents in acute cardiac care
Q33333976	The use of glycoprotein IIb/IIIa inhibitors in patients with coronary artery disease
Q34675290	The use of the glycoprotein IIb/IIIa receptor antagonists during percutaneous coronary intervention
Q35035390	The vulnerable plaque and acute coronary syndromes
Q34155640	Therapeutic adjuncts for immediate transfer to the catheterization laboratory in patients with acute coronary syndromes
Q28187576	Therapeutic approaches in arterial thrombosis
Q73599594	Therapeutic heparin concentrations augment platelet reactivity: implications for the pharmacologic assessment of the glycoprotein IIb/IIIa antagonist abciximab
Q28137808	Therapeutic monoclonal antibodies
Q74322967	Thrombin activation and late restenosis after percutaneous transluminal coronary angioplasty
Q33387648	Thrombocytopenia following percutaneous coronary intervention.
Q28180848	Thrombolysis and antithrombotic therapy for coronary artery disease
Q34298004	Thrombolytic and antiplatelet therapy in peripheral vascular disease with use of reteplase and/or abciximab. The SCVIR Consultants' Conference; May 22, 2000; Orlando, FL. Society for Cardiovascular and Interventional Radiology
Q41667008	Thrombosis, antithrombotic agents, and the antithrombotic approach in cardiac disease
Q102135395	Ticagrelor versus clopidogrel in elective percutaneous coronary intervention (ALPHEUS): a randomised, open-label, phase 3b trial
Q73254330	Ticlopidine enhances the platelet inhibitory capacity of abciximab in vitro
Q78194765	Time course, magnitude, and consistency of platelet inhibition by abciximab, tirofiban, or eptifibatide in patients with unstable angina pectoris undergoing percutaneous coronary intervention
Q83179323	Tirofiban versus abciximab: tirofiban is administered at suboptimal dosages when evaluated in an arterial thrombosis model in non-human primates
Q33504832	Tirofiban. A review of its use in acute coronary syndromes
Q77812474	Toward the elimination of stent thrombosis
Q33183365	Transradial approach for coronary angioplasty in the setting of acute myocardial infarction: a dual-center registry
Q42757934	Treatment and prognosis after myocardial infarction. Echocardiography and rescue angioplasty are effective for high risk patients
Q33641463	Treatment of non-ST-segment-elevation acute coronary syndromes with platelet glycoprotein IIb/IIIa inhibitors: an emergency department perspective
Q72999601	Treatment of unstable angina: role of antithrombotic therapy
Q35943383	Trends and comparison of female first authorship in high impact medical journals: observational study (1994-2014)
Q33754183	Trials of glycoprotein IIb-IIIa inhibitors in non-ST-segment elevation acute coronary syndromes: applicability to the practice of medicine in the United States
Q56567720	Trials of platelet glycoprotein IIb/IIIa receptor antagonists during percutaneous coronary revascularization
Q56944494	Triple antiplatelet therapy during percutaneous coronary intervention is associated withimproved outcomes including one-year survival
Q47409928	Unfractionated Heparin during Elective PCI: Fixed Dose or Weight Adjusted?
Q34674179	Unfractionated versus fractionated heparin for percutaneous coronary intervention
Q41589794	Unmet therapeutic needs in the management of acute ischemia
Q73193136	Unraveling the pathophysiology of percutaneous coronary intervention: is it in the genes?
Q38547536	Unstable angina and non-Q wave myocardial infarction: does the clinical diagnosis have therapeutic implications?
Q28192025	Unstable angina and non-ST-segment elevation myocardial infarction: perspectives on combination therapy
Q38118745	Update on platelet glycoprotein IIb/IIIa inhibitors: recommendations for clinical practice
Q33942871	Update on the interaction between aspirin and angiotensin-converting enzyme inhibitors
Q31942397	Upstream use of tirofiban in patients admitted for an acute coronary syndrome in hospitals with or without facilities for invasive management. PRISM-PLUS Investigators.
Q40523922	Use of GPIIb/IIIa inhibitors in cardiovascular medicine
Q41737302	Use of abciximab in interventional cardiology
Q42118681	Use of antiplatelet inhibitors in peripheral vascular interventions.
Q33369310	Use of glycoprotein IIb/IIIa inhibitors in unstable angina and non-ST-elevation myocardial infarction
Q35209701	Use of nonantiarrhythmic drugs for prevention of sudden cardiac death
Q33876187	Use of platelet glycoprotein IIb/IIIa inhibitors in diabetics undergoing PCI for non-ST-segment elevation acute coronary syndromes: impact of clinical status and procedural characteristics
Q94558111	Value of Antiplatelet Therapy in Preventing Thrombotic Events in Generalized Vascular Disease
Q74791813	Value of the American College of Cardiology/American Heart Association stenosis morphology classification for coronary interventions in the late 1990s
Q78073491	Variability in abciximab (ReoPro) prescribing: evidence based or budget driven?
Q43798414	Variable response to the biological inhibition of platelets by abciximab in patients subjected to percutaneous coronary angioplasty
Q95440899	Variations between countries in invasive cardiac procedures
Q50908717	Vascular access site complications after percutaneous coronary intervention with abciximab in the Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) trial.
Q33970367	Vascular drugs in the new millennium
Q46494898	Which heparin and how much?
Q38851769	Why we need intravenous antiplatelet agents
Q81359097	[Acute coronary syndrome: unstable angina and myocardial infarction]
Q74442723	[Percutaneous suture of femoral artery access sites after diagnostic heart catheterization and or coronary intervention. Safety and effectiveness of a new arterial suture technic]
Q80413635	[Perioperative therapy with antiplatelet agents]
Q79305336	[Results of the performance of percutaneous coronary revascularization procedures without the presence of heart surgery]
Q77295540	[Stent restenosis: therapy concepts and possibilities for prevention]
Q73538114	[The efficacy of platelet IIb/IIIa receptor blockers in acute coronary syndromes]
Q73229963	[Therapy of acute coronary syndrome with glycoprotein IIb/IIIa antagonists]
Q73038813	[Therapy of acute coronary syndrome. Aspirin, heparin, low-molecular-weight heparin, hirudin and GP-IIb/IIIa blockers]
Q80391619	[Transradial approach for percutaneous coronary stenting in the treatment of acute myocardial infarction]
Q78852049	[Treatment of unstable angina: early invasive strategy]
Q56944503	abciximab survival advantage following percutaneous coronary intervention is predicted by clinical risk profile
Q26829973	2012 ACCF/AHA focused update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Associat

P356	DOI	10.1056/NEJM199706123362401
P698	PubMed publication ID	9182212

P2093	author name string	EPILOG Investigators
P433	issue	24
P407	language of work or name	English	Q1860
P921	main subject	heparin	Q190016
		revascularization	Q7317735
P304	page(s)	1689-1696
P577	publication date	1997-06-01
P1433	published in	The New England Journal of Medicine	Q582728
P1476	title	Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization
P478	volume	336

Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization

scientific article published in June 1997

Reverse relations